GlassScriptPhysician profile
Douglas C Nathanson
NPI 1679679484
$46,617.67
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $13K · 2021: $12K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $20,303.06 | 2019-2021 | |
| Celgene Corporation | $9,404.40 | 2020-2021 | |
| Genzyme Corporation | $7,212.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $5,532.14 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $3,313.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $287.70 | 2019-2020 | |
| Emd Serono, INC. | $283.51 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $131.53 | 2019-2020 | |
| Lilly USA, LLC | $73.66 | 2019 | |
| Medtronic USA, INC. | $53.55 | 2019 | |
| Acorda Therapeutics, INC | $22.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Nathanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.